Floatz logo

Eovist

Cognitive Function

GuerbetPhase 4 / ApprovedActive
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

149 Active assets in the Cognitive Function cohort.

Asset / SponsorPhaseRating
Ginkgo Biloba Extract
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 4BBB
Nicotine
University of Southern California
Phase 2BBB
Rivastigmine
Singapore General Hospital
Phase 4BBB
Oxybutynin
University of Alberta
Phase 4BBB
LEVODOPA
Vanderbilt University Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Eovist is also rated in:

liver cancerDormant
B
Indicative ·
63 / 100
View asset →
Contrast MediaDormant
B
Indicative ·
63 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →